Publications

Total Publications

56

Manuscripts
Oral
Presentations
Poster
Presentations
6
6
44
 Manuscripts  Oral Presentation  Poster Presentation

Manuscripts

Moon A.M., Watkins S.E., Lok A.S., Firpi-Morell R.J., Trinh H.N., Kupec J.T., Schoen C., Neuschwander-Tetri B.A., Barritt A.S. IV. Opioid Use is More Common in Non-Alcoholic Fatty Liver Disease Patients with Cirrhosis, Higher Body Mass Index and Psychiatric Disease. Digestive Diseases, September 2020. Published via Advanced Release (accepted, unedited manuscript) doi: 10.1159/000511074.

Ethan M. Weinberg, Huy N. Trinh, Roberto J. Firpi, Kalyan Ram Bhamidimarri, Samuel Klein, Jonathan Durlam, Stephanie Watkins, K. Rajender Reddy, Michael Weiss, Richard C. Zink, Anna S. Lok. Lean Americans With Nonalcoholic Fatty Liver Disease Have Lower Rates of Cirrhosis and Co-morbid Diseases. Clinical Gastroenterology and Hepatology, July 2020; doi: 10.1016/j.cgh.2020.06.066.

Barritt AS IV, Gitlin N, Klein S, Lok AS, Loomba R, Malahias L, Powell M, Vos MB, Weiss M, Cusi K, Neuschwander-Tetri B, Sanyal A. Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: the TARGET-NASH study. Contemporary Clinical Trials, October 2017; 61: 33-38; doi: 10.1016/j.cct.2017.07.015

3

Levy C, Bowlus CL, Carey E, Crawford JM, Deane K, Mayo MJ, Kim WR, Fried MW. A Real-World Observational Cohort of Patients with Primary Biliary Cholangitis: TARGET-PBC Study Design and Rationale. Hepatology Communications, March 2018; 2(4) 484-491; doi.org/10.1002/hep4.1173.

1

Katrina Abuabara, Jonathan I Silverberg, Eric L Simpson, Amy S Paller, Lawrence F Eichenfield, Robert Bissonnette, James Krueger, John E. Harris, Laura Dalfonso, Stephanie E Watkins, Julie M Crawford, D Thaci, Emma Guttman-Yassky. International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale. BMJ Open, November 2020; .

1

Michael W. Fried, Julie M. Crawford, Andrea R. Mospan, Stephanie E. Watkins, Breda Munoz Hernandez, Richard C. Zink, Sherry Elliott, Kyle Burleson, Charles Landis, K. Rajender Reddy, Robert S. Brown, Jr. Patient Characteristics and Outcomes of 11,721 Patients with COVID19 Hospitalized Across the United States. Clinical Infectious Disease, August 2020; doi: 10.1093/cid/ciaa1268.

1

Posters/Presentations

Arun J. Sanyal, Meng Wang, Kenneth Cusi, A. Sidney Barritt IV, Mark Muthiah, Stephanie Watkins, K. Rajender Reddy, Roberto Firpi-Morell, Paul Thuluvath, Kalyan Ram Bhamidimarri, Michael W. Fried. A Pragmatic Clinical Prognostic Classification Suitable for Universal Application Stratifies Patients with NAFLD by Risk of Mortality and Both Hepatic and Extrahepatic Outcomes. AASLD. Virtual Poster. November, 2020.

Hannah P. Kim, Michael O. Idowu, Richard C. Zink, Andrea R. Mospan, Michael Roden, Philip Newsome, Anna Lok, Paul Thuluvath, Jawahar Taunk, Michael W. Fried, Arun J. Sanyal, A. Sidney Barritt IV. Heterogeneous Documentation and Poor Concordance of NASH Pathology May Limit its Clinical Utility in Real-World Practice. AASLD. Virtual Poster. November, 2020.

A. Sidney Barritt IV, K. Rajender Reddy, L. Michael Weiss, Paul J. Thuluvath, Andrea R. Mospan, Cheryl Schoen, Kenneth Cusi, Arun J. Sanyal. Fibrosis Assessed by Non-Invasive Tests is Similar to Liver Biopsy for Predicting Clinical Outcomes: A TARGET-NASH Study. AASLD. Virtual Poster. November, 2020.

Peter Mesenbrink, A. Sidney Barritt IV, Rohit Loomba, Philip N. Newsome, Arun J. Sanyal, Richard C. Zink. Predicting advanced fibrosis using non-invasive clinical tests and modern machine learning methods in TARGET-NASH. EASL. Virtual poster presentation. August 2020.

Andrew Moon, Stephanie Watkins, Miguel Malespin, Cheryl Schoen, L Michael Weiss, Rohit Loomba, PJ Thulavath, Rajender Reddy, A. Sidney Barritt IV, Arun Sanyal, Brent Tetri. Weight loss and change in alanine aminotransferase (ALT) among patients with nonalcoholic fatty liver disease (NAFLD) receiving standard care in real world clinical practice: TARGET-NASH. EASL. August 2020.

Kenneth Cusi, Michael Roden, A. Sidney Barritt IV, Roberto Firpi, Virginia Clark, Sam Klein, Anna S Lok, Philip Newsome, Karen Corbin , Miriam Vos, Rajender Reddy, Cheryl Schoen, Andrea Mospan, Jawahar Taunk, Kathleen Wyne, Brent Neuschwander-Tetri, Arun Sanyal. Clinical Profile of Nonalcoholic Fatty Liver Disease in Adults with Type 2 Diabetes Mellitus. ADA. Virtual presentation. June, 2020.

Andrew M. Moon, Stephanie Watkins, Miguel Malespin, Cheryl Schoen, L. Michael Weiss, Rohit Loomba, Paul J. Thuluvath, K. Rajender Reddy, A. Sidney Barritt IV, Arun J. Sanyal, Brent A. Neuschwander-Tetri. Weight Loss and Change in Alanine Aminotransferase (ALT) Among Patients with Nonalcoholic Fatty Liver Disease (NAFLD) Receiving Standard Care in Real World Clinical Practice: TARGET-NASH. Accepted to DDW. Abstract published May, 2020 in Gastroenterology.

Malespin M, Barritt AS IV, Watkins S, Schoen C, Konerman M, Corbin K, Trinh HN, Weiss LM, Reddy R, Loomba R, Kemmer N, Lok AS. Incidence of Achieving Weight Loss Goals in Usual Clinical Practice: Results for the TARGET-NASH Observational Cohort. AASLD, Boston, MA. Oral presentation. November, 2019.

AS Barritt IV, AS Lok, KR Reddy, LM Weiss, RJ Firpi, PJ Thuluvath, HN Trinh, S Djedjos, R Haubrich, A Billin, B Koch II, R Zink, AJ Sanyal, K Cusi, BA Neuschwander-Tetri. Routinely Available Noninvasive Tests Perform Well in Identifying Patients with Advanced Fibrosis Due to NASH: Data from the TARGET-NASH Observational Cohort. AASLD. Boston, Massachusetts. Poster presented November 2019.

Bryan Rudolph, Jacob Bilhartz, Cheryl Schoen, Praveen Selvakumar, Sirish Palle, Stavra Xanthakos, Patrick McKiernan, Alisha Mavis, A. Sidney Barritt IV, Miriam Vos. Patient Reported Outcomes Among Pediatric Patients with Nonalcoholic Fatty Liver Disease: TARGET-NASH. AASLD. Boston, Massachusetts. Poster presented November 2019. 

A. Sidney Barritt IV, Stephanie Watkins, Brent Neuschwander-Tetri, Cheryl Schoen, Roshani Desai, Miriam Vos, Laura Malahias, Miguel Malespin, Philip Newsome, Rajender Reddy, Jawahar Taunk, Roberto Firpi, Arun Sanyal. Patterns of Medication Use Among Adult Patients with Elevated Serum ALT Levels in Patients with NAFLD: TARGET-NASH. AASLD. Boston, Massachusetts. Poster presented November 2019. 

Vandana Khungar, Anna S. Lok,  L. Michael Weiss, Paul Thuluvath, Kalyan Ram Bhamidimarri, Derek Gazis,  Laura Malahias, K. Rajender Reddy. The Prescribing Patterns and Use of Statins in Patients with Nonalcoholic Fatty Liver Disease. EASL Vienna, Austria.  Poster presented April, 2019.

Andrew M. Moon, Anna S. Lok, Roberto J. Firpi-Morell, K. Vandana Khungar, Huy Ngoc Trinh, Justin T. Kupec, Cheryl Schoen, Laura Malahias, A. Sidney Barritt IV. Opioid use in patients with NAFLD: prevalence and association with comorbidities and disease severity.  EASL Vienna, Austria.  Poster presented April, 2019.

Ethan Weinberg, Huy N. Trinh, Roberto J Firpi, Kalyan Ram Bhamidimarri, Samuel Klein, Laura Malahias, Richard C. Zink, Anna Lok. Lean NAFLD patients have lower prevalence of cardiovascular, metabolic and severe liver disease compared to overweight or obese patients with NAFLD. EASL Vienna, Austria. Poster presented April, 2019.

Desai R, Tetri B et al. Characterization of polypharmacy in patients with NAFLD. Accepted for poster presentation at AASLD in San Francisco, CA. November, 2018.

Cusi K, Barritt AS IV, Firpi R, Klein S, Lok AS, Loomba R, Malahias L, Reddy KR, Schoen C, Taunk J, Neuschwander-Tetri BA, Wyne K, Sanyal AJ. Clinical Profile of Adults with Nonalcoholic Steatohepatitis (NASH) with and without Type 2 Diabetes Mellitus (T2DM). ADA. Orlando, Florida. Poster presented June, 2018.

Palle S, Bilhartz J, Lavine J, Malahias L, Miloh T, Rudolph B, Schoen C, Xanthakos SA, McKiernan P, Vos MB. Nonalcoholic Fatty Liver Disease in Children in the U.S.: Clinical Characteristics of Participants Enrolled in TARGET-NASH. DDW. Washington, DC. Poster presented June, 2018.

Sanyal A, Cusi K, Firpi-Morell R, Gitlin N, Levy C, Malahias L, Reddy KR, Schoen C, Weiss LM, Lok AS. Real World Evidence Showing High Rates of Cardiovascular Events in NAFLD Patients Regardless of Liver Disease. DDW. Washington, DC. Poster presented June, 2018.

deLemos A, Barritt AS IV, Bhamidimarri KR, Landis C, Malahias L, Malespin M, Schoen C, Taunk J, Thuluvath P, Trinh HN, Neuschwander-Teteri BA. Sustained Elevation in Alkaline Phosphatase is Associated with Greater Disease Severity in Real World NAFLD in TARGET-NASH. DDW. Washington, DC. Poster presented June, 2018.

Vos MB, Bilhartz J, Malahias L, McKiernan P, Miloh T, Palle S, Rudolph B, Schoen C, Xanthakos SA. ALT Elevation in Children with Nonalcoholic Fatty Liver Disease Commonly Surpasses Levels Reported in the Literature. Pediatric Academic Societies Meeting, Toronto, Canada. Oral Presentation. May, 2018.

Barritt AS IV, Gitlin N, Klein S, Lok AS, Loomba R, Malahias L, DeMuth GE, Crawford JM, Reddy KR, Trinh HN, Vos MB, Weiss M, Cusi K, Newschwander-Tetri BA, Sanyal AJ. Nonalcoholic Fatty Liver Disease in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-NASH. AMCP, Boston, MA. Poster presented April, 2018.

Sanyal A, Cusi K, Firpi-Morell R, Gitlin N, Levy C, Malahias L, Reddy KR, Schoen CL, Weiss LM, Lok AS. Real World Evidence Showing High Rates of Cardiovascular Events in NAFLD Patients Regardless of Liver Disease. EASL, Paris, France. Poster presented April, 2018.

Barritt AS IV, Gitlin N, Klein S, Lok AS, Loomba R, Malahias L, DeMuth GE, Crawford JEM, Reddy KR, Trinh HN, Vos MB, Weiss M, Cusi K, Neuschwander-Tetri BA, Sanyal AJ. Nonalcoholic Fatty Liver Disease in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-NASH. NASH-TAG Conference. Park City, Utah. Poster presented January, 2018.

Barritt AS IV, Gitlin N, Klein S, Lok AS, Loomba R, Malahias L, DeMuth GE, Crawford JM, Reddy KR, Trinh HN, Vos MB, Weiss M, Cusi K, Neuschwander-Tetri BA, Sanyal AJ. Nonalcoholic Fatty Liver Disease in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-NASH. HEP DART Conference, Kona, Hawaii. Poster presented December, 2017.

Barritt AS IV, Gitlin N, Klein S, Lok AS, Loomba R, Malahias L, DeMuth GE, Crawford JM, Reddy KR, Trinh HN, Vos MB, Weiss M, Cusi K, Neuschwander-Tetri BA, Sanyal AJ. Nonalcoholic Fatty Liver Disease in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-NASH. AASLD, Washington, DC. Poster presented October, 2017.

Vos MB. The Trans-Atlantic Pediatric TARGET-NASH Study: Advancing Clinical Care for Pediatric NAFLD. International Conference on Fatty Liver, Seville, Spain. Oral Presentation. June, 2017.

Barritt AS IV, Cusi K, Klein S, Crawford JEM, DeMuth GE, Malahias L, Neuschwander-Tetri BA, Sanyal A, Vos, MB. Design and Rationale for a Real World Observational Cohort of Patients with Nonalcoholic Fatty Liver Disease: The TARGET-NASH Study. International Conference on Fatty Liver, Seville, Spain. Poster presented June, 2017.

Vos MB. A real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH Study. NASH Biomarkers Workshop 2017, Washington, DC. Oral Presentation. May, 2017.

Vos MB, Barritt AS IV, Gitlin N, Klein S, Lok AS, Loomba R, Malahias L, Weiss LM, Cusi K, Neuschwander-Tetri BA, Sanyal A. A Real World Observational Cohort of Patients with Nonalcoholic Fatty Liver Disease: The TARGET-NASH Study. NASH Biomarkers Workshop 2017, Washington DC. Poster presented May, 2017.

5

24

Elizabeth Carey, Helen Smith, Megan McLaughlin, April Thompson, Andrea Mospan, Robert Sandefur, Richard C. Zink, W. Ray Kim, Cynthia Levy. The Pervasive Impact of Pruritus on Quality of Life in Patients with Primary Biliary Cholangitis (PBC): Real World Experience in TARGET-PBC. AASLD. Virtual Poster. November, 2020.

Marlyn J. Mayo, Andrea Mospan, Helen Smith, Megan McLaughlin, April Thompson, Robert Sandefur, Richard C. Zink, Christopher Bowlus, Cynthia Levy. Pruritus in Primary Biliary Cholangitis is Under-Treated in Clinical Practice: Results from TARGET-PBC. AASLD. Virtual Poster. November, 2020.

Marlyn J. Mayo, Christopher L. Bowlus, Elizabeth J. Carey, Ester C. Little, Karen Deane, Richard Zink, Robert Sandefur, W. Ray Kim, Cynthia Levy. Primary biliary cholangitis (PBC)-autoimmune hepatitis (AIH) overlap syndrome: Characteristics and response to obeticholic acid (OCA) in TARGET-PBC, a diverse, large United States (US) real- world cohort. DDW. San Diego, California. Poster presented May 2019.

Cynthia Levy, Marlyn J. Mayo, Elizabeth J. Carey, Ester C. Little, W. Ray Kim, Karen Deane, Richard Zink, Robert Sandefur, Christopher L. Bowlus. Change in Lipids: Characteristics and Response to Obeticholic Acid (OCA) in TARGET-PBC, a Diverse, Large United States (US) Real-world Cohort. DDW. San Diego, California. Poster presented May 2019.

Marlyn J. Mayo, Christopher L. Bowlus, Elizabeth J. Carey, Ester C. Little, Karen Deane, Richard Zink, Robert Sandefur, W. Ray Kim, Cynthia Levy. Primary biliary cholangitis (PBC)-autoimmune hepatitis (AIH) overlap syndrome: Characteristics and response to obeticholic acid (OCA) in TARGET-PBC, a diverse, large United States (US) real- world cohort. EASL. Vienna, Austria. Poster presented April 2019.

Cynthia Levy, Marlyn J. Mayo, Elizabeth J. Carey, Ester C. Little, W. Ray Kim, Karen Deane, Richard Zink, Robert Sandefur, Christopher L. Bowlus. Change in Lipids: Characteristics and Response to Obeticholic Acid (OCA) in TARGET-PBC, a Diverse, Large United States (US) Real-world Cohort. EASL. Vienna, Austria. Poster presented April 2019.

Carey EJ, Levy C, Mayo MJ, Bowlus CL, Deane K, Sandefur RA, Laliberte PH, Zink RC and Kim WR. Patient-Reported Indicators of Health and Symptoms in US Patients with Primary Biliary Cholangitis (PBC). AASLD. San Francisco, California. Poster presented November, 2018.

Levy C, Bowlus CL, Carey EJ, DeMuth G, Deane K, Mayo MJ, Kim WR, Bacon BR, Bernstein D, Thuluvath PJ, Weiss LM, Iloeje U, Erickson M, Strauss M, Fried MW. Primary Biliary Cholangitis (PBC) in the U.S.: Real World Effectiveness of Obeticholic Acid in TARGET-PBC. DDW. Washington, DC. Poster presented June, 2018.

Levy C, Bowlus CL, Carey EJ, DeMuth G, Deane K, Mayo MJ, Kim WR, Bacon BR, Bernstein D, Thuluvath PJ, Weiss LM, Fried MW. Primary Biliary Cholangitis (PBC) in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-PBC. DDW. Washington, DC. Poster presented June, 2018.

Levy C, Bowlus CL, Carey EJ, DeMuth G, Deane K, Mayo MJ, Kim WR, Bacon BR, Bernstein D, Thuluvath PJ, Weiss LM, Iloeje U, Erickson M, Strauss M, Fried MW. Primary Biliary Cholangitis (PBC) in the U.S.: Real World Effectiveness of Obeticholic Acid in TARGET-PBC. EASL. Paris, France. Poster presented April, 2018. 

Levy C, Bowlus CL, Carey EJ, DeMuth G, Deane K, Mayo MJ, Kim WR, Bacon BR, Bernstein D, Thuluvath PJ, Weiss LM, Fried MW. Primary Biliary Cholangitis (PBC) in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-PBC. EASL, Paris, France. Poster presented April, 2018. 

11

Roniel Cabrera, Amit Singal, Massimo Colombo, Anthony El-Khoueiry, R. Kate Kelley, Hannah Lee, Laura Malahias, Tim Meyer, Pippa Newell, Neehar Parikh, Bruno Sangro, K Rajender Reddy, Richard Zink, Adrian Di Bisceglie.  Management of Hepatocellular Carcinoma (HCC) in a Real Life Multinational, Longitudinal, Observational Study (TARGET-HCC). Poster presented at EASL, Vienna, Austria, April 2019.

Neehar D. Parikh, Laura Malahias, Robert S. Brown Jr., Roniel Cabrera, Patricia Denise Jones, Charles Landis, Hannah Lee, Parvez Mantry, Edward Mena, Nishant Poddar, K. Rajender Reddy, Roshan Shrestha, Paul Thuluvath, Richard C. Zink, Amit G. Singal. Regional, racial/ethnic, and socioeconomic disparities and treatment outcomes in patients with hepatocellular carcinoma (HCC) in the US.  ASCO-GI. San Francisco, California.  Presented January 2019.

2

Benjamin H. Click, Edward L. Barnes, Benjamin Cohen, Miguel D. Regueiro, Marla C Dubinsky, John S. Hanson, Bruce E. Sands, David T. Rubin, Srikar Guntaka, Derek Gazis, Julie M. Crawford, Millie D. Long. Objective Disease Activity Assessment and Therapeutic Drug Monitoring is Lacking Prior to Biologic Therapy Changes in Routine Inflammatory Bowel Disease Clinical Practice: TARGET-IBD. Accepted to DDW. Abstract published May, 2020 in Gastroenterology.

Edward L. Barnes, John S. Hanson, Miguel Regueiro, Sumona Saha, Bruce E. Sands, David T. Rubin, Marla C. Dubinsky, Corey A. Siegel, Derek R. Gazis, Julie M. Crawford, Millie D. Long. Medication Use and Comorbidities Among Elderly as Compared to Younger Patients with Inflammatory Bowel Disease in the TARGET-IBD Cohort. ACG. San Antonio, Texas. Poster presented October, 2019. Presidential Poster Award, Outstanding Poster Presenter Award (Dr. Barnes).

Edward L. Barnes, John S. Hanson, Miguel Regueiro, Sumona Saha, Bruce E. Sands, David T. Rubin, Marla C. Dubinsky, Corey A. Siegel, Derek R. Gazis, Julie M. Crawford, Millie D. Long. Medication Use and Comorbidities Among Elderly as Compared to Younger Patients with Inflammatory Bowel Disease in the TARGET-IBD Cohort. ECCO. Vienna, Austria. Encore poster presented February, 2020. Best Digital Oral Presentation Award (Dr. Sands).

Nitin Gupta, Bruce E. Sands, Miguel Regueiro, Marla C. Dubinsky, David T. Rubin, John S. Hanson, Faten Aberra, Michael Weiss, Stephanie Watkins, Derek Gazis, Millie D. Long. Oral Mesalamine Use in Crohn’s Disease After Implementation of the American College of Gastroenterology Guidelines: A TARGET-IBD Cohort Study. ECCO. Vienna, Austria. Encore ACG poster presented February 2020. 

Nitin Gupta, Bruce E. Sands, Miguel Regueiro, Marla C. Dubinsky, David T. Rubin, John S. Hanson, Faten Aberra, Michael Weiss, Stephanie Watkins, Derek Gazis, Millie D. Long. Oral Mesalamine Use in Crohn's Disease After Implementation of the American College of Gastroenterology Guidelines: A TARGET-IBD Cohort Study. ACG. San Antonio, Texas. Poster presented October, 2019.

Long M, Sands B et al. Development of a Novel Longitudinal Observational Cohort of Adult and Pediatric Patients with Inflammatory Bowel Disease: TARGET-IBD. ACG, Philadelphia, Pennsylvania. Poster presented October, 2018.

1

5

DE Bernstein, HN Trinh, ER Schiff, CI Smith, RC Zink, AS Lok. Effectiveness of Tenofovir Alafenamide in Patients with Chronic Hepatitis B Treated in Usual Clinical Practice: Results from the TARGET-HBV Observational Cohort Study. AASLD. Boston, Massachusetts. Poster presented November 2019. 

DE Bernstein, HN Trinh, ER Schiff, CI Smith, RC Zink, AS Lok. Effectiveness of Tenofovir Alafenamide in Patients with Chronic Hepatitis B Treated in Usual Clinical Practice: Results from the TARGET-HBV Observational Cohort Study. HEP DART. Kauai, Hawaii. Encore poster presented December 2019. 

2